07th week of 2019 patent applcation highlights part 24 |
Patent application number | Title | Published |
20190048007 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES - The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT | 2019-02-14 |
20190048008 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS - The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of Cezanne 1. The invention further relates to the use of DUB inhibitors in the treatment of cancer. | 2019-02-14 |
20190048009 | Methods for Preparing Bis-Tetrahydroisoquinoline-Containing Compounds - (−)-Jorumycin, ecteinascidin 743, saframycin A and related compounds, methods of preparing the same, formulations comprising the compounds, and methods of treating proliferative diseases with the same are provided. | 2019-02-14 |
20190048010 | Mercaptopurine Hemihydrate - Provided herein is a new mercaptopurine form, as a hemihydrate, and methods of making and using the same. | 2019-02-14 |
20190048011 | COMPOSITIONS COMPRISING FOLIC ACID DERIVATIVES, THEIR PREPARATIONS AND METHODS OF USE - Described herein are methods for making folic acid derivatives, intermediates, pharmaceutical compositions and uses thereof. | 2019-02-14 |
20190048012 | Triazolopyridines And Triazolopyrimidines That Lower Stress-Induced P-Tau - Pharmaceutical compounds, compositions, methods, and uses therefor are presented using selected triazolopyridines and triazolopyrimidines to inhibit or reduce phosphorylation of tau proteins or that act as antagonists of corticotropin-releasing factor. Viewed from another perspective, compounds, compositions, and methods are presented for treating or preventing symptoms of Alzheimer's disease by inhibiting or reducing the phosphorylation of tau proteins. | 2019-02-14 |
20190048013 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO - Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: | 2019-02-14 |
20190048014 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) - The disclosure is directed to compounds of Formula I | 2019-02-14 |
20190048015 | SEMICONDUCTING POLYMER - Compounds of formula (I) and polymers comprising at least a structure of formula (II), wherein T | 2019-02-14 |
20190048016 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS - The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. | 2019-02-14 |
20190048017 | METHOD FOR CATALYTIC PREPARATION OF HYDROMORPHONE, HYDROCODONE, AND OTHER OPIATES - Methods are provided for efficient preparation of hydromorphone or hydrocodone by redox isomerization of morphine or codeine allylic alcohols, respectively, using transition metal aminophosphine catalysts formed in situ. | 2019-02-14 |
20190048018 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF OXYCODONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF - The presently described technology provides compositions comprising aryl carboxylic acids and, for example NSAIDs, chemically conjugated to oxycodone (4,5-α-epoxy-14-hydroxy-17-methylmorphinan-6-one) to form novel prodrugs/compositions of oxycodone, including benzoates, salicylates, propionates, fenamates, and acetates, which have a decreased potential for abuse of oxycodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology. | 2019-02-14 |
20190048019 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY - The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases, e.g., cancers (e.g., breast cancer, prostate cancer, lymphoma, lung cancer, pancreatic cancer, ovarian cancer, neuroblastoma, or colorectal cancer), benign neoplasms, angiogenesis, inflammatory diseases, fibrosis (e.g., polycystic kidney disease), autoinflammatory diseases, and autoimmune diseases in a subject. | 2019-02-14 |
20190048020 | DEUTERIUM-MODIFIED CFTR MODULATORS - This invention relates to novel 4,4,5,5,7,7-hexamethyl-5,7-dihydro-4H-thieno[2,3-c]pyranyl compounds, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering cystic fibrosis transmembrane conductance regulator (CFTR) modulators. | 2019-02-14 |
20190048021 | ORGANIC SEMICONDUCTOR COMPOSITION, ORGANIC THIN FILM COMPRISING SAME, AND USE THEREOF - In the present invention, a composition comprising two types of thienothiophene compounds selected from the group consisting of the compounds indicated by formulas (1) to (4) (in formulas (1) to (4), either one of R | 2019-02-14 |
20190048022 | MACROCYCLIC IMMUNOMODULATORS - Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I) or (II): | 2019-02-14 |
20190048023 | CRYSTAL OF COMPOUND HAVING JAK-INHIBITING ACTIVITY - An object of the present invention is to provide a compound with an excellent JAK1 inhibitory activity. | 2019-02-14 |
20190048024 | SYNTHETIC PROCESSES AND INTERMEDIATES - The invention provides synthetic processes and synthetic intermediates that can be used to prepare a compound of formula (I): or a salt thereof. | 2019-02-14 |
20190048025 | Preparation Of Difluoro Chelato Borate Salts - A process for preparing a difluoro chelato borate salt comprising an anion A of formula (I) | 2019-02-14 |
20190048026 | Boron-Containing Small Molecules - This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate. | 2019-02-14 |
20190048027 | BETA-LACTAMASE INHIBITOR - A beta-lactamase inhibitor having a formula (I). Also provided is a method of using the beta-lactamase inhibitor for prevention or treatment of diseases. | 2019-02-14 |
20190048028 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. | 2019-02-14 |
20190048029 | MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USES THEREOF - The present invention provides compounds, compositions thereof, and methods of using the same. | 2019-02-14 |
20190048030 | SILYLATED DERIVATIVES OF AROMATIC HETEROCYCLES - The present disclosure describes novel silylated heteroaromatic derivatives, including those prepared by methods comprising the use of hydrosilanes and at least one strong base, the definition of strong base now also including hydroxide, especially KOH. | 2019-02-14 |
20190048031 | Process for preparing 3-glycidyloxypropyltrialkoxysilanes - A process can prepare a 3-glycidyloxypropylalkoxysilane of formula (I), (R′)O—(CH | 2019-02-14 |
20190048032 | Process for preparing tris[3-(alkoxysilyl)propyl] isocyanurates - A process can prepare an isocyanurate compound by hydrosilylation. The compound is a tris[3-(trialkoxysily)propyl] isocyanurate, a tris[3-(alkyldialkoxysilyl)propyl] isocyanurate, and/or a tris[3-(dialkylalkoxysilyl)propyl] isocyanurate. The process includes (A) preparing a mixture of at least one carboxylic acid, a platinum catalyst, and 1,3,5-triallyl-1,3,5-triazine-2,4,6(1H,3H,5H)-trione; (B) heating the mixture to a temperature in the range of 40 to 140° C.; (C) adding at least one H-silane among a hydrotrialkoxysilane, a hydroalkyldialkoxysilane, and a hydrodialkylalkoxysilane to the mixture; (D) adding at least one alcohol to the mixture prepared in step (C); and (E) isolating the isocyanurate compound. | 2019-02-14 |
20190048033 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS - Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R | 2019-02-14 |
20190048034 | METHOD FOR PRODUCING ALPHA-HALO-TETRAACYL-GLUCOSE - There is provided an efficient and excellent preparation method of an α-halo-tetraacyl-glucose which is suitable for industrial preparation, which comprises reacting D-glucose or lower alkyl D-glucoside with a reactive derivative of a carboxylic acid and a metal halide to prepare the α-halo-tetraacyl-glucose represented by the formula (III): | 2019-02-14 |
20190048035 | PROCESSES FOR PREPARING MACROLIDES AND KETOLIDES AND INTERMEDIATES THEREFOR - The invention described herein pertains to processes for the preparation of macrolide antibacterial agents. In particular, the invention pertains to processes for preparing macrolides and ketolides from erythromycin A. | 2019-02-14 |
20190048036 | EXCITONIC QUANTUM COMPUTING MEDIATED BY CHROMOPHORE-EMBEDDED 1-, 2-, AND 3-DIMENSIONAL DNA SCAFFOLDS - Using nucleotide architectures to very closely and precisely placed chromophores that produce quantum coherent excitons, biexcitons, and triexcitons upon excitement to create excitonic quantum wires, switching, and gates that would then form the basis of quantum computation. Creating the various excitons and controlling the timing of the excitons would be performed using light of the corresponding wavelength and polarization to stimulate the corresponding chromophores. | 2019-02-14 |
20190048037 | PREPARATION OF BILE ACIDS AND INTERMEDIATES THEREOF - Synthetic methods for preparing deoxycholic acid and intermediates thereof are provided. | 2019-02-14 |
20190048038 | METHOD FOR GENERATING CELL-PENETRATING STAPLED PEPTIDES THAT LACK NONSPECIFIC MEMBRANE-LYTIC PROPERTIES FOR THERAPEUTIC TARGETING - Methods for generating cell-permeable hydrocarbon-stapled and/or stitched peptides lacking nonspecific membrane lytic properties and methods for using such peptides to target cellular proteins for experimental investigation and/or therapeutic benefit. | 2019-02-14 |
20190048039 | FUNCTIONALIZED NANOPARTICLES FOR ENHANCED AFFINITY PRECIPITATION OF PROTEINS - The present invention provides a nanoparticle capable of binding specifically to a target protein in a solution and precipitating with the target protein out of the solution upon addition of the target protein to the solution. The precipitation may be reversed release the target protein from the nanoparticle, which may be reused for precipitating the target protein. Also provided are a method for purifying a target protein by affinity precipitation using the nanoparticle without chromatography and a method for preparing the nanoparticle. | 2019-02-14 |
20190048040 | Substituted Urea Depsipeptide Analogs as Activators of the CLPP Endopeptidase - In one aspect, the invention relates to substituted urea depsipeptide analogs, derivatives thereof, and related compounds, which are useful as activators the ClpP endopeptidease; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating infectious disease using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2019-02-14 |
20190048041 | METHODS AND COMPOSITIONS FOR ANTIBODY-EVADING VIRUS VECTORS - The present invention provides AAV capsid proteins comprising a modification in the amino acid sequence and virus vectors comprising the modified AAV capsid protein. The invention also provides methods of administering the virus vectors and virus capsids of the invention to a cell or to a subject in vivo. | 2019-02-14 |
20190048042 | NON-NATURALLY OCCURING PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV) AND METHODS OF USING - A non-naturally occurring porcine reproductive and respiratory syndrome virus (PRRSV) is provided herein, and methods of making and using the non-naturally occurring PRRSV also are provided. | 2019-02-14 |
20190048043 | Compositions and Methods Related to HIV-1 Immunogens - The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections. | 2019-02-14 |
20190048044 | METHOD FOR EXTRACTING 2',3'-CYCLIC NUCLEOSIDE MONOPHOSPHATES - It relates to a method for preparation of four kinds of 2′, 3′-cNMPs (2′, 3′-cAMP, 2′, 3′-cGMP, 2′, 3′-cCMP and 2′, 3′-cUMP), comprising steps of: (1) extract genomic DNA and amplify gene If3; (2) ligate If3 gene to expression plasmid to construct a recombinant vector, and transfer the recombinant vector to | 2019-02-14 |
20190048045 | ACTINOBACILLUS PLEUROPNEUMONIAE RECOMBINANT TOXIN PROTEIN AND APPLICATION THEREOF - The invention relates to a recombinant | 2019-02-14 |
20190048046 | PROTEIN A MUTANTS HAVING HIGH ALKALI RESISTANCE AND METHODS OF USE THEREOF - A series of protein A mutants having high alkali resistance, and methods of using the protein A mutants are provided. The protein A mutants have a high binding affinity for regions of immunoglobulin proteins other than the complementarity determining regions. The protein A mutants can be coupled to a solid support for immunoglobulin isolation, or conjugated to a label for immunoglobulin detection. This series of protein A mutants have high chemical stability under alkaline conditions of pH 13-14, and can also be used as chromatography ligands for purification procedures that use alkaline solutions under harsh conditions, such as Clean-In-Place (CIP). Also provided are methods of immunoglobublin separation and purification, and alkali regeneration of affinity chromatography medium that uses protein A as a ligand. | 2019-02-14 |
20190048047 | COMPOSITIONS AND METHODS FOR TREATMENT OF CELIAC DISEASE - The invention provides agents and vaccines for treating and diagnosing celiac disease. In particular, the present invention provides a combination of three peptides that are useful for treating and diagnosing celiac disease in a large proportion of patients. | 2019-02-14 |
20190048048 | FUSION PROTEINS AND METHODS FOR IDENTIFYING BROMODOMAIN INHIBITING COMPOUNDS - The present invention relates methods for identifying bromodomain inhibiting compounds. | 2019-02-14 |
20190048049 | CARGOMERS - Cargomers comprising apolipoprotein molecules complexed with amphipathic molecules and one or more cargo moieties. | 2019-02-14 |
20190048050 | PEPTIDE-BASED METHODS FOR TREATING NEUROLOGICAL INJURY - Methods for treating and preventing neurodegenerative disease, neurological injury, including stroke, via administration of Transient receptor potential M2 (TRPM2)-inhibitors. The inhibitors may be administered in conjunction with another therapeutic agent or therapeutic regimen. The peptides may be administered to a human male. The peptides may be administered within eight hours of a neurological injury, such as a stroke. | 2019-02-14 |
20190048051 | POLYPEPTIDES TARGETING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 AND ALPHA V BETA 3 INTEGRIN - Polypeptides comprising variant vascular endothelial growth factor sequences are provided. The polypeptides are useful in cancer imaging, cancer diagnosis, monitoring and treatment as well as treatment of diseases characterized by excessive neovascularization. | 2019-02-14 |
20190048052 | ANTI-MICROBIAL PEPTIDES AND COATINGS - Antimicrobial peptides and methods of use are provided. | 2019-02-14 |
20190048053 | PEPTIDES AND USE OF SAME IN THE TREATMENT OF DISEASES, DISORDERS OR CONDITIONS ASSOCIATED WITH A MUTANT P53 - An isolated peptide is provided. The peptide comprises an amino acid sequence arranged in a space and configuration that allow interaction of the peptide with the DNA Binding Domain (DBD) of p53 through at least one residue of the DBD by which pCAP 250 (SEQ ID NO: 1) binds the DBD, wherein the peptide at least partially reactivates a mutant p53 protein, with the proviso that the peptide is not SEQ ID NO: 59-382. | 2019-02-14 |
20190048054 | Mesenchymal Stem Cells Expressing Biomarkers that Predict the Effectiveness of Mesenchymal Stem Cells for Treating Diseases and Disorders - Isolated mesenchymal stem cells, which produce mRNA encoding TSG-6 protein or a biologically active fragment, derivative, or analogue thereof in an amount of at least a first preselected amount, or produce mRNA encoding TSG-6 protein or a biologically active fragment, derivative, or analogue thereof in an amount that does not exceed a second preselected amount, as determined by an assay, such as a RT-PCR assay. Isolated mesenchymal stem cells that produce mRNA encoding TSG-6 protein or a biologically active fragment, derivative, or analogue thereof in an amount of at least the first preselected amount are useful in treating diseases, conditions, and disorders associated with inflammation, while isolated mesenchymal stem cells that produce mRNA encoding TSG-6 protein or a biologically active fragment, derivative, or analogue thereof in an amount that does not exceed the second preselected amount are useful in treating bone diseases, conditions, and disorders, including bone injuries. | 2019-02-14 |
20190048055 | ALT-803 IN COMBINATION WITH ANTI-CD38 ANTIBODY FOR CANCER THERAPIES - The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases. | 2019-02-14 |
20190048056 | HETERODIMERS OF IL-15 AND IL-15R ALPHA TO INCREASE THYMIC OUTPUT AND TO TREAT LYMPHOPENIA - The present invention provides method for promoting the maturation and export of T cells from thymic tissue by contacting the thymic tissue with supraphysiological levels of interleukin (IL)-15. The present invention also provides methods for preventing, alleviating, reducing, and/or inhibiting lymphopenia or peripheral depletion of lymphocytes in a patient in need thereof by administering to the patient IL-15. | 2019-02-14 |
20190048057 | COMPOSITIONS COMPRISING TREM2 AND METHODS OF USE THEREOF - The present invention provides TREM2 constructs. TREM2 constructs of the invention are polynucleotide sequences encoding a polypeptide, wherein the polypeptide comprises at least one TREM2 or fragment thereof and a targeting moiety and optionally comprising a signal peptide and/or a purification moiety. The present invention also provides isolated polypeptides encoded by TREM2 constructs, vectors comprising TREM2 constructs, isolated cells comprising said vectors, and methods of use thereof. | 2019-02-14 |
20190048058 | TCR LIBRARIES - The present invention relates to a library of particles, the library displaying a plurality of different T cell receptors (TCRs), wherein the plurality of TCRs consists essentially of TCRs comprising an alpha chain variable domain and a beta chain variable domain, wherein the alpha chain variable domain comprises a TRAV12-2 gene product and the beta chain variable domain comprises a TRBV gene product. | 2019-02-14 |
20190048059 | TCR LIBRARIES - The present invention relates to a library of particles, the library displaying a plurality of different T cell receptors (TCRs), wherein the plurality of TCRs consists essentially of TCRs comprising an alpha chain variable domain and a beta chain variable domain, wherein the alpha chain variable domain comprises a TRAV9-2 gene product and the beta chain variable domain comprises a TRBV9 gene product. | 2019-02-14 |
20190048060 | CHIMERIC ANTIGEN RECEPTOR MEDIATED CELL TARGETING - Disclosed herein are methods and compositions for engineering cells to express a CAR where the cells also have inactivated TCR, HPRT, PD1, CISH and/or HLA genes, using engineered nucleases comprising at least one DNA binding domain and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding nucleases, vectors comprising polynucleotides encoding nucleases and cells comprising polynucleotides encoding nucleases and/or cells comprising nucleases are also provided. | 2019-02-14 |
20190048061 | ANTI-CD37 CHIMERIC ANTIGEN RECEPTORS AND IMMUNE CELLS EXPRESSING THEM - The present invention relates to nucleic acid molecules encoding chimeric antigen receptors (CARs) against the antigen CD37. The CARs disclosed herein have complementarity-determining regions (CDRs) derived from the potent monoclonal anti-CD37 antibody HH1, and may be used in immunotherapy to target cells expressing CD37. Such immunotherapy has a particular use in the treatment of B-cell cancers. The CARs of the present invention are highly functional in the redirection of immune cells to kill CD37+ cells, and include humanised CARs of particular use in medical therapy. The present invention also includes vectors comprising the above-described nucleic acid molecules, immune effector cells expressing the aforementioned CARs and the use of such immune effector cells in therapy, particularly adoptive transfer therapy, for cancer, including B-cell malignancies. | 2019-02-14 |
20190048062 | A RECOMBINANT CHIMERIC PROTEIN FOR SELECTINS TARGETING - The invention discloses a recombinant protein (P-selectin glycoprotein ligand-1 and Neural Retina-specific Leucine Zipper) PSGL-1-NRL chimeric protein comprising a Selectin Binding domain and a non-covalent dimerization domain, which is a leucine zipper and is more preferably the leucine zipper domain of the human or mouse Neural Retina-specific Leucine Zipper. The chimeric protein further comprises a covalent dimerization domain with at least one cysteine suitable to form a disulfide bridge with another chimeric protein to form a homodimer. In the chimeric protein, the PSGL-1 domain corresponds to the extracellular region of Human PSGL-1 and is more preferably the selectin binding region of the mature protein. The chimeric protein is correctly post-translationally modified and is efficiently expressed in a mammalian system. It is sulfated, O-linked glycosylated and sialylated and binds P, E and L selectin, allowing in vivo and in vitro targeting for diagnostic or therapeutic purposes. | 2019-02-14 |
20190048063 | METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITION - In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction. | 2019-02-14 |
20190048064 | ANTIBODIES - The invention provides an immunoassay kit providing an immunoassay kit comprising one or more analyte specific antibodies or fragments thereof, characterised that the antibody or fragment thereof comprises one or more non-disulphide cross-links between at least one heavy chain or fragment thereof and at least one light chain or fragment thereof of the analyte- specific antibodies or fragments thereof. | 2019-02-14 |
20190048065 | MONOCLONAL ANTIBODIES SPECIFIC FOR THE PIII ANTIGEN OF HUMAN ADENOVIRUS (ADV), PRODUCED AND SECRETED BY CELL HYBRIDOMAS, USEFUL FOR DETECTION AND DIAGNOSIS OF ADV INFECTION - The present invention refers to monoclonal antibodies, or fragments thereof, which recognize the pIII protein of the Adenovirus (ADV), useful for developing diagnostic methods of ADV infection in humans. Particularly, it refers to a monoclonal antibody or fragment thereof comprising a variable region of the heavy chain having a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No: 1 or SEQ ID No: 5 and a variable region of the light chain having a sequence with at least a 90%, 95% or 99% of identity with the SEQ ID No: 2 or SEQ ID No: 6. It also is addressed to the nucleotide sequences which define said antibodies, in vitro and/or ex vivo diagnostic methods of ADV infection in a biological sample using said monoclonal antibodies, and diagnostic kits for detecting ADV comprising at least one monoclonal antibody against ADV according to the above description. | 2019-02-14 |
20190048066 | HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN - The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to Ebola virus glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing Ebola virus activity, thus providing a means of treating or preventing Ebola virus infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the Ebola virus for preventing viral attachment and/or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines. | 2019-02-14 |
20190048067 | HIV ANTIBODY COMPOSITIONS AND METHODS OF USE - This invention relates to novel anti-HIV antibodies that can be used in the treatment and detection of human immunodeficiency virus (HIV). These antibodies exhibit a high degree of sensitivity and can provide a broad range of specificity. | 2019-02-14 |
20190048068 | METHOD FOR DIAGNOSING AND TREATING CANCER USING ANTIBODIES THAT BIND TO C1 INACTIVATOR, C REACTIVE PROTEIN AND/OR COMPLEMENT COMPONENT C4 - The present invention relates among other things to a novel method of diagnosing cancer by applying antibodies that bind to human C1 inactivator, antibodies that bind to human C Reactive Protein and/or antibodies that bind to human Complement Component C4. Also the present invention relates to a pharmaceutical composition comprising one or more antibodies that bind to C inactivator, antibodies that bind to human C Reactive Protein and/or antibodies that bind to human Complement Component C4 for use in the treatment of cancer, inhibiting growth of cancer and/or inhibiting proliferation of cancer. | 2019-02-14 |
20190048069 | HUMAN ANTIBODIES THAT BIND HUMAN TNF-ALPHA AND METHODS OF PREPARING THE SAME - Methylglyoxal (MGO)-modified recombinant TNF-alpha antibodies (e.g., Adalimumab) are identified. MGO modification decreases binding between Adalimumab and TNF-alpha. Methods are disclosed for reducing the presence of MGO-modified antibodies in the production of Adalimumab TNF-alpha antibodies. | 2019-02-14 |
20190048070 | REDUCTION OF HIGH MOLECULAR WEIGHT SPECIES, ACIDIC CHARGE SPECIES AND FRAGMENTS IN A MONOCLONAL ANTIBODY COMPOSITION - Alterations in bioreactor cell culture feeding to an extended or continuous feed following an initial period of no feeding reduces the level of high molecular weight, acid charge, and fragment species of monoclonal antibodies expressed in the culture, and enhances the level of afucosylated species of monoclonal antibodies expressed in the culture. Regular fucose infusions following an initial period of no feed media infusion reduces the level of afucosylated species of monoclonal antibodies expressed in the culture. Cell culture manipulation may be used to modulate the level of species of monoclonal antibodies. | 2019-02-14 |
20190048071 | ANTIBODIES FOR IL-17C - The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis. | 2019-02-14 |
20190048072 | USE OF IL-1beta BINDING ANTIBODIES - Use of an IL-1β binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment and/or prevention of cancer with at least partial inflammatory basis. | 2019-02-14 |
20190048073 | ANTI-GD3 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES - The present invention provides for anti-GD3 antibodies, and ADCs and methods for preparing and using the same. | 2019-02-14 |
20190048074 | APLNR Modulators and Uses Thereof - The present invention provides apelin receptor (APLNR) modulators that bind to APLNR and methods of using the same. The invention includes APLNR modulators such as antibodies, or antigen-binding fragments thereof, that inhibit or attenuate APLNR-mediated signaling. The invention includes APLNR modulators such as antibodies, or antibody fusion proteins thereof, that activate APLNR-mediated signaling. According to certain embodiments of the invention, the antibodies or antigen-binding fragments or antibody fusion proteins are fully human antibodies that bind to human APLNR with high affinity. The APLNR modulators of the invention are useful for the treatment of diseases and disorders associated with APLNR signaling and/or APLNR cellular expression, such as cardiovascular diseases, angiogenesis diseases, metabolic diseases and fibrotic diseases. | 2019-02-14 |
20190048075 | SYNERGISTIC ANTI-CD47 THERAPY FOR HEMATOLOGIC CANCERS - Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2. | 2019-02-14 |
20190048076 | COMPOSITION AND METHOD FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS - The present invention provides a composition and method for treating, delaying the onset, delaying progression of, reducing the incidence of or reducing the severity of amyotrophic lateral sclerosis, in a subject. The composition in some embodiments of the invention is an immunoglobulin derived Fc fragment which binds and partially antagonizes the action of CD16. | 2019-02-14 |
20190048077 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF SURGICAL ADHESIONS - Aspects of the present disclosure include methods of treating a subject to reduce adhesion formation, the method comprising administering to a subject in need of thereof an agent that that targets adhesion-formation by injured mesothelial cells. The agent can act at a variety of checkpoints in the development of adhesions by injured mesothelial cells, including: targeting the injured mesothelial cells for destruction, recruiting inflammatory macrophages to the site of adhesion, preventing neutrophil recruitment to the site of adhesion, and/or inhibiting the expression or activity of a gene product whose expression is induced in the injured mesothelial cells. Compositions and kits for performing the methods are also provided. | 2019-02-14 |
20190048078 | ENGINEERED ANTIBODY FC VARIANTS FOR ENHANCED SERUM HALF LIFE - In some aspects, mutant or variant Fc domains are provided that exhibit increased binding to FcRn and increased half-life after administration in vivo. The Fc domain may be comprised in a glycosylated or aglycosylated antibody. Methods for using the mutant or variant Fc domains or polypeptides comprising the mutant or variant Fc domains are also provided. | 2019-02-14 |
20190048079 | Methods and Compositions Involving NKG2D Inhibitors and Cancer - Embodiments methods and compositions involving inhibitors of the immunoreceptor Natural Killer Group 2, Member D, (NKG2D) for inhibiting tumor progression and treating cancer. | 2019-02-14 |
20190048080 | BISPECIFIC COUPLED ANTIBODY, PREPARATION METHOD AND APPLICATION THEREOF - A bispecific coupled antibody, a preparation method and an application thereof are provided. Specifically, an anti-CTLA-4 humanized single-chain antibody fragment (scFv) is provided, which has the advantages of high affinity and strong specificity. Using the anti-CTLA-4 antibody to construct a recombinant bispecific conjugated antibody (fusing a humanized anti-Her-2 full antibody (Trastuzumab) with anti-CTLA-4 human single-chain antibody (scFv, single-chain antibody fragment)) is capable of significantly enhancing the body's immune response and maintaining or enhancing the activation state of T cells. | 2019-02-14 |
20190048081 | METHOD FOR TREATING CANCER - Provided is a method for treating a cancer in a subject in need thereof. The method comprises administering to the subject an anti-PD-1 agent in combination with one or more anticancer agents. | 2019-02-14 |
20190048082 | PSEUDOTYPED ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES - Described herein are pseudotyped oncolytic viruses comprising nucleic acids encoding an engager molecule. In some embodiments, the pseudotyped oncolytic viruses comprises nucleic acids encoding an engager molecule and one or more therapeutic molecules. Pharmaceutical compositions containing the pseudotyped oncolytic virus and methods of treating cancer using the pseudotyped oncolytic viruses are further provided herein. | 2019-02-14 |
20190048083 | REGULATORY T CELL MEDIATOR PROTEINS AND USES THEROF - The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates αCD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon αCD3/αGITR stimulation. This protein has been designated T | 2019-02-14 |
20190048084 | ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS - The present invention relates to therapeutic combinations and methods for treating cancers using combination therapy. | 2019-02-14 |
20190048085 | MODIFIED CELLS FOR IMMUNOTHERAPY - The present invention relates to engineered immune cells expressing antigen receptors, such as a T cell receptor (TCR) or a chimeric antigen receptor (CAR), as well as antibody targeting PD-L1. Also provided are related nucleic acids, vectors, compositions and method for enhancing the immune response towards cancers and pathogens. | 2019-02-14 |
20190048086 | ANTI-CITRULLINATED HLA POLYPEPTIDE ANTIBODIES AND USES THEREOF - The present invention relates to methods for treating an autoimmune disease in a human subject mediated by the presence of a citrullinated epitope QKCitAA, QRCitAA, or RRCitAA in the subject, the method comprising administering a therapeutica1ly effective amount of an antibody or a specific binding fragment thereof that specifically binds to citrullinated epitope QKCitAA, QRCitAA, or RRCitAA. Further aspects of the invention include an antibody or a specific binding fragment thereof, that specifically binds to a human citrullinated epitope QKCitAA, QRCitAA, or RRCitAA. | 2019-02-14 |
20190048087 | Fully Human Antibodies that Bind to Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) - There is disclosed compositions and methods relating to anti-VEGFR2 antibodies. More specifically, there is disclosed fully human antibodies that bind VEGFR2, VEGFR2-binding fragments and derivatives of such antibodies, and VEGFR2-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having various cancers. | 2019-02-14 |
20190048088 | COMBINATION OF HUMAN ANTI-FGFR4 ANTIBODY AND SORAFENIB - The present invention relates to the medical use of antibodies against the FGF receptor 4 (FGFR4) combined with Sorafenib, in particular for the prevention or treatment of hyperproliferative diseases associated with FGFR expression, overexpression or hyperactivity. | 2019-02-14 |
20190048089 | Antagonistic Antibodies Specifically Binding Human CD40 and Methods of Use - The present invention relates to antagonistic antibodies specifically binding human CD40, polynucleotides encoding the antibodies or antigen-binding fragments thereof, and methods of making and using the foregoing. | 2019-02-14 |
20190048090 | AGENTS BINDING SPECIFICALLY TO HUMAN CADHERIN-17, HUMAN CADHERIN-5, HUMAN CADHERIN-6 AND HUMAN CADHERIN-20 RGD MOTIF - The disclosure relates to agents binding specifically to human cadherin 17 (CDH17), and/or to human cadherin 5 (CDH5), and/or to human cadherin 6 (CDH6), and/or to human cadherin 20 (CDH2O). The disclosure also relates to the use of these agents in therapy, methods for diagnosis and/or prognosis and/or stratification of a cancer in a subject, and pharmaceutical compositions comprising said agents. The disclosure also relates to cancer markers and markers of metastasis. | 2019-02-14 |
20190048091 | TREATMENT FOR MULTIPLE MYELOMA (MM) - The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens. | 2019-02-14 |
20190048092 | ANTIBODY THERAPEUTICS THAT BIND CD38 - There is disclosed compositions and methods relating to or derived from anti-CD38 antibodies. More specifically, there is disclosed fully human antibodies that bind CD38, CD38-antibody binding fragments and derivatives of such antibodies, and CD38-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease. | 2019-02-14 |
20190048093 | MULTISPECIFIC NK ENGAGER PROTEIN - Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease. | 2019-02-14 |
20190048094 | REDIRECTING IMMUNE RESPONSES - Agents that specifically bind tumor-associated antigens (TAA) and comprise an exogenous polypeptide or peptide that can be presented by a tumor cell are disclosed. The TAA-binding agents may include antibodies and/or bispecific agents. Also disclosed are methods of using the agents for redirecting an existing immune response against tumor cells and/or treatment of diseases such as cancer. | 2019-02-14 |
20190048095 | COMPOUNDS AND METHODS FOR THE TREATMENT OF TROP2 POSITIVE DISEASES - The present invention generally relates to compounds comprising antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to TROP2 (TACSTD2). The present invention also relates to methods of using such TROP2-binding molecules for diagnosing and treating diseases, such as malignancies. | 2019-02-14 |
20190048096 | Anti-CTLA-4 Antibodies and Uses Thereof - The present invention provides antibodies that bind to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing CTLA-4 activity, thus providing a means of activating T-cells and/or for treating a disease or disorder such as cancer or viral infection. | 2019-02-14 |
20190048097 | ANTI-HtrA1 ANTIBODIES AND METHODS OF USE THEREOF - The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders. | 2019-02-14 |
20190048098 | BISPECIFIC ANTIBODY PLATFORM - Provided herein are solutions to the heavy and light chain mispairing problems in bispecific antibodies. One part of the solution involves Fc regions that are engineered in their CH3 domains by lysine repositioning to drive heterodimerization of the two heavy chains of the bispecific antibody. The second part of the solution involves a modification of one of the two Fab arms of the bispecific antibody so as to prevent mispairing of light chains in the bispecific antibody. Specifically, the CH1 and CL domains of one of the Fab arms of the bispecific antibody are substituted with an IgE CH2 domain or an IgM CH2 domain. | 2019-02-14 |
20190048099 | METHOD FOR PRODUCING CELLULOSE DERIVATIVE, AND CELLULOSE DERIVATIVE - A method for producing a cellulose derivative, including reacting a mixed acid anhydride having two particular types of acyl groups with cellulose in the presence of a base catalyst in an organic solvent having an electron pair-donating property to form a cellulose derivative with the two types of acyl groups derived from the mixed acid anhydride, the acyl groups being introduced at hydroxy groups in the cellulose. | 2019-02-14 |
20190048100 | A PROCESS AND APPARATUS FOR MANUFACTURING SUGAR ACID - The present invention relates to a novel process for manufacturing a sugar acid for the use in the agricultural market as an adjuvant wherein the process includes the following steps of providing a reactor and introducing a source of nitric acid, water and a source of starch into the reactor to form a mixture and further includes introducing an external heat source to the mixture to ascertain a mixture temperature of at least 70° C. and discontinuing the external heat source once the mixture reaches about 70° C.; and further enabling an internal heat source in the form of an exothermic reaction to occur between the reagents for at least two (2) hours. The invention also relates to the use of the product as obtained from the process. | 2019-02-14 |
20190048101 | Rubber and By-Product Extraction Systems and Methods - Systems and methods for extracting useful by-products and natural rubber from non- | 2019-02-14 |
20190048102 | METHOD FOR MODIFYING A NATURAL RUBBER, AND MODIFIED NATURAL RUBBER - The present invention relates to a process for modifying a natural rubber, comprising at least the following steps:
| 2019-02-14 |
20190048103 | METHOD OF PRODUCING POLYETHER RUBBER - A method of production of a polyether rubber containing unit expressed by the following general formula (1) in 0.1 mol % or more and less than 30 mol % obtained by reacting a polyether rubber containing epihalohydrin monomer unit in 0.1 mol % or more and a nitrogen atom-containing aromatic heterocyclic compound by kneading in the presence of an acid acceptor containing at least a hydrotalcite having a nitrogen adsorption specific surface area as measured by a BET method of 10 m | 2019-02-14 |
20190048104 | MODIFIED CONJUGATED DIENE-BASED POLYMER AND METHOD FOR PREPARING THE SAME - The present invention relates to a modified conjugated diene-based polymer, and more particularly, provides a modified conjugated diene-based polymer including a functional group derived from a modifier including a compound represented by Formula 1, and a method for preparing the same. | 2019-02-14 |
20190048105 | THREE DIMENSIONAL DEPOSITION METHOD TO CREATE LAYERS OF POLYMERIC MATERIAL ONTO AN OBJECT - A process for providing one or more thermoset polymeric materials onto an object is disclosed wherein said process comprises at least the following steps:
| 2019-02-14 |
20190048106 | Olefin Coordination Polymerization Catalyst, And Preparation Method And Application Thereof - The present invention relates to an olefin coordination polymerization catalyst and a preparation method and application thereof. The olefin polymerization catalyst consists of a primary catalyst mainly prepared from a magnesium compound, a transition metal halide, a C | 2019-02-14 |